AMENDMENT NO. 1 TO RGN-259 LICENSE AGREEMENT (PAN ASIA)License Agreement • November 14th, 2019 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 1 to License Agreement (this “Amendment”), dated September 17, 2019, amends that certain License Agreement (the “Agreement” or the “License Agreement”), dated effective March 7, 2014, by and between RegeneRx Biopharmaceuticals, Inc., (hereinafter “Licensor”), and GtreeBNT Co., Ltd. (formerly Digital Aria Co., Ltd.) (hereinafter “Licensee”), each a “Party” and, collectively, the “Parties.”
AMENDMENT N. 1 TO LICENSE AGREEMENTLicense Agreement • November 14th, 2019 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • New York
This amendment agreement (hereinafter “Amendment n. 1”), dated February 25, 2019 (hereinafter the “Amendment Date”), is entered into by and between RegeneRx Biopharmaceuticals, Inc., a company organized and existing under the laws of the state of Delaware, wit h offices at 15245 Shady Grove Road, Suite 470, Rockville, MD 20850, U.S.A. (hereinafter “Licensor”), and Lee’s Pharmaceutical (HK) Limited, a Hong Kong registered company with its principal place of business at 1/F, Building 20E, Phase 3, Hong Kong Science Park, Shatin, New Territories, Hong Kong (hereinafter “Licensee”). Licensor and Licensee are individually referred to as a “Party” and collectively as the “Parties.”
